JP4263192B2 - アスタキサンチンを利用する方法及び組成物 - Google Patents
アスタキサンチンを利用する方法及び組成物 Download PDFInfo
- Publication number
- JP4263192B2 JP4263192B2 JP2005518375A JP2005518375A JP4263192B2 JP 4263192 B2 JP4263192 B2 JP 4263192B2 JP 2005518375 A JP2005518375 A JP 2005518375A JP 2005518375 A JP2005518375 A JP 2005518375A JP 4263192 B2 JP4263192 B2 JP 4263192B2
- Authority
- JP
- Japan
- Prior art keywords
- astaxanthin
- composition
- dogs
- cats
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims description 154
- 235000013793 astaxanthin Nutrition 0.000 title claims description 154
- 239000001168 astaxanthin Substances 0.000 title claims description 154
- 229940022405 astaxanthin Drugs 0.000 title claims description 154
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims description 153
- 239000000203 mixture Substances 0.000 title claims description 87
- 238000000034 method Methods 0.000 title claims description 25
- 241000282472 Canis lupus familiaris Species 0.000 claims description 67
- 241000282326 Felis catus Species 0.000 claims description 59
- 241001465754 Metazoa Species 0.000 claims description 58
- 235000013305 food Nutrition 0.000 claims description 27
- 230000028993 immune response Effects 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 235000015872 dietary supplement Nutrition 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000024932 T cell mediated immunity Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 230000028996 humoral immune response Effects 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 description 30
- 230000004044 response Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 25
- 230000000378 dietary effect Effects 0.000 description 22
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 21
- 230000005951 type IV hypersensitivity Effects 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 18
- 235000016709 nutrition Nutrition 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 230000003013 cytotoxicity Effects 0.000 description 16
- 231100000135 cytotoxicity Toxicity 0.000 description 16
- 210000004698 lymphocyte Anatomy 0.000 description 16
- 238000002255 vaccination Methods 0.000 description 16
- 210000000822 natural killer cell Anatomy 0.000 description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 14
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 13
- 235000013734 beta-carotene Nutrition 0.000 description 13
- 239000011648 beta-carotene Substances 0.000 description 13
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 13
- 229960002747 betacarotene Drugs 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 235000021466 carotenoid Nutrition 0.000 description 13
- 150000001747 carotenoids Chemical class 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000035764 nutrition Effects 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 13
- 210000000265 leukocyte Anatomy 0.000 description 12
- 108010074051 C-Reactive Protein Proteins 0.000 description 11
- 102100032752 C-reactive protein Human genes 0.000 description 11
- 230000037213 diet Effects 0.000 description 11
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 230000036737 immune function Effects 0.000 description 8
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 102100032768 Complement receptor type 2 Human genes 0.000 description 6
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000016784 immunoglobulin production Effects 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 229940031348 multivalent vaccine Drugs 0.000 description 6
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 235000019750 Crude protein Nutrition 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000012682 canthaxanthin Nutrition 0.000 description 4
- 239000001659 canthaxanthin Substances 0.000 description 4
- 229940008033 canthaxanthin Drugs 0.000 description 4
- 235000020930 dietary requirements Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 235000012680 lutein Nutrition 0.000 description 4
- 239000001656 lutein Substances 0.000 description 4
- 229960005375 lutein Drugs 0.000 description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- -1 lipid peroxides Chemical class 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000008601 oleoresin Substances 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241000346074 Eugeissona tristis Species 0.000 description 2
- 241000168517 Haematococcus lacustris Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108010070551 Meat Proteins Proteins 0.000 description 2
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 235000019728 animal nutrition Nutrition 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 229940008450 astaxanthin 5 mg Drugs 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 235000014590 basal diet Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- BIPAHAFBQLWRMC-LOFNIBRQSA-N epsilon,epsilon-carotene-3,3'-diol Chemical compound CC1=CC(O)CC(C)(C)C1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CC(O)CC1(C)C BIPAHAFBQLWRMC-LOFNIBRQSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000005061 intracellular organelle Anatomy 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960002385 streptomycin sulfate Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 235000010930 zeaxanthin Nutrition 0.000 description 2
- 239000001775 zeaxanthin Substances 0.000 description 2
- 229940043269 zeaxanthin Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFFIDZXUXFLSSR-UHFFFAOYSA-N 1-methyl-N-[2-(4-methylpentan-2-yl)-3-thienyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound S1C=CC(NC(=O)C=2C(=NN(C)C=2)C(F)(F)F)=C1C(C)CC(C)C PFFIDZXUXFLSSR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000168525 Haematococcus Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000277275 Oncorhynchus mykiss Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000241627 Pfaffia Species 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000009430 Thespesia populnea Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930193647 Tunaxanthin Natural products 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- MQZIGYBFDRPAKN-UWFIBFSHSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-UWFIBFSHSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001707 blastogenic effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940070533 lutein 20 mg Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000005249 tunaxanthin Nutrition 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Feed For Specific Animals (AREA)
Description
百分率及び比率はすべて、特に指示がない限り、重量で計算される。百分率及び比率はすべて、特に指示がない限り、総組成物を基準にして計算される。
本明細書の組成物は、本明細書に記載のどの特徴若しくは実施形態を含んでもよく、本質的に成ってもよく、又は成ってもよい。
本明細書の組成物は、コンパニオンアニマルによる使用に適合されている。本明細書で使用するとき、用語「コンパニオンアニマル」は、家畜を意味しており、イヌ、ネコがそれに含まれる。この点で、当業者にはよく理解されるように、本明細書に記載の組成物の主な用途は、コンパニオンアニマル用であり、したがって、組成物は、そのように配合される。
さらに本発明者らは、そのような動物において、循環アスタキサンチンが、血中白血球によってかなりの量吸収され、高比重リポタンパク質(HDL)に結合することを発見した。本発明者らはまた、アスタキサンチンが様々な細胞内小器官にも分配されることを発見した。このように、白血球の様々な小器官にアスタキサンチンが吸収されると、(1)これらの細胞を酸素フリーラジカルの攻撃から保護し、且つ/又は(2)核に関わる事象を直接的に調節すると考えられている。故に、イヌ及びネコのようなコンパニオンアニマルに有効量のアスタキサンチンを含有する組成物を与えると、当該動物の体内組織内の重要な細胞部位にアスタキサンチンが供給され、それが、これらの動物における免疫機能の上方調節及び健康の改善をもたらす。
本発明の組成物は、炭水化物源をさらに含んでよい。米、トウモロコシ、ミロ、サトウモロコシ、大麦、小麦などのようなグレイン又はシリアルが、供給源の例である。
組成物はまた、乾燥ホエイ及び他の乳製品副産物のような他の物質も含有してよい。
本発明の方法は、炎症の軽減又は免疫反応の増強のために、コンパニオンアニマル、特にイヌ又はネコに、本発明の組成物を経口投与する(すなわち、摂食による)ことを含む。
(イヌにおけるアスタキサンチン補給の効果)
(材料及び方法)
メスのビーグル犬(生後9〜10ヶ月;体重8.2±0.2kg;コバンス・リサーチ・プロダクツ社(Covance Research Products Inc.)、ミシガン州カラマズー(Kalamazoo))をランダムに割り振って、1日に0mg、10mg、20mg、又は40mgのアスタキサンチン(ヘマトコッカス・プルビアリス(Haematococcus pluvialis)由来のアスタキサンチン109g/含油樹脂1kgの濃縮物、アストラザンシン(astraZanthin)(商標)、ラ・エー・ラボラトリーズ(La Haye Laboratories)、ワシントン州レドモンド(Redmond))を16週間与えた(n=14/処置)。アスタキサンチンを市販の基礎食餌(アイムス社(The Iams Co.)、オハイオ州ルイスバーグ(Lewisburg))に組み込み、1日に2回与えた(食品200g/日)。食餌組成物は、次の通り(g/kg)であった:水分85.3、タンパク質275.8、灰分60.7、脂肪115.0、Ca9.9、P9.3、粗繊維21.3、総エネルギー18,914kJ/kg;n−6:n−3脂肪酸比は7.9であった。イヌを、温度調節(20〜22℃)及び光調節(14時間光(hour light))施設内で、2×3mの檻(1つの檻にイヌ2匹)で飼育した。第0週、第4週、第8週、及び第16週に体重を記録した。免疫機能を評価するために、第0週、第6週、及び第12週に血液を採取した。すべてのイヌに第12週及び第14週の2回ワクチンを接種し(ヴァンガード5(Vanguard 5)(商標)、スミスクライン・ビーチャム(Smithkline Beacham)、ペンシルベニア州ウェストチェスター(West Chester))、ワクチン接種後の免疫反応を評価するために、第16週に再び血液を採取した。
特異的細胞毒性(%)=1−(ODエフェクター+標的−ODエフェクター)/OD標的×100。
研究全体を通じて、食餌は、体重に有意な影響を及ぼさなかった。第0週及び第16週の平均体重は、それぞれ、8.18±0.16kg及び8.57±0.11kgであった。アスタキサンチンは、補給前のすべてのイヌの血漿中で検出されず、補給されなかったイヌの血漿では研究の間検出されなかった。しかし、アスタキサンチンは、16週を通じて、用量依存的に増加した(図5)。最高血中濃度は、補給されたイヌすべてにおいて第6週までに観察された。
血液学。研究全体を通じて、血液学は一般に、食事の影響を示さなかった。
(ネコにおけるアスタキサンチン補給の効果)
(材料及び方法)
メスの短毛のイエネコ(生後8〜9ヶ月;体重3.2±0.04kg;リバティ・ファームズ(Liberty Farms)、ニューヨーク州ウェイバリー(Waverly))をランダムに割り振って、1日に(平均摂取食品量90g/日に基づいて)0mg、1mg、5mg、又は10mgのアスタキサンチン(ヘマトコッカス・プルビアリス(Haematococcus pluvialis)由来のアスタキサンチン109g/含油樹脂1kgの濃縮物、アストラザンシン(astraZanthin)(商標)、ラ・エー・ラボラトリーズ(La Haye Laboratories)、ワシントン州レドモンド(Redmond))を12週間与えた(n=14/食餌)。アスタキサンチンを市販の基礎食餌(アイムス社(The Iams Co.)、オハイオ州ルイスバーグ(Lewisburg))に組み込み、適宜与えた。食餌組成物は、次の通り(g/kg)であった:水分63.1、タンパク質350.6、灰分62.7、脂肪213.6、Ca10.0、P7.6、粗繊維7.1、総エネルギー21,707kJ/kg;n−6:n−3脂肪酸比は9.9であった。ネコを、温度調節(20〜22℃)及び光調節(14時間光)施設内で飼育し、第0週、第4週、第8週、及び第12週に体重を測定した。免疫機能を評価するために、第0週及び第8週に血液を採取した。抗原投与後の免疫反応に対するアスタキサンチンの食餌効果を評価するために、すべてのネコに、ワクチン(フェロセル(Felocell)(商標)、ファイザー(Pfizer)、ニューヨーク)を2回(第8週及び第10週)接種し、第12週に血液を採取して同一の免疫パラメータを測定した。
特異的細胞毒性(%)=1−(ODエフェクター+標的−ODエフェクター)/OD標的×100。
第0週及び第12週の平均体重は、それぞれ3.23±0.04kg及び3.22±0.06kgで、処置間に有意な差はなかった。補給されなかったネコの血漿ではアスタキサンチンは検出されなかったが、アスタキサンチン濃度には、通常、用量依存的な増加があった(図7)。第8週に血漿アスタキサンチン濃度が最初に急速に増加した後、血漿アスタキサンチンは、緩やかになったものの、第12週の終わりまで増加を続けた。
バス(Bass)ら、アメリカ獣医学研究雑誌(Am.J.Vet.Res.)、37、1355〜1357(1976)。
ベンネドセン(Bennedsen)ら、免疫学通信(Immunology Lett.)、70、185〜189(1999)。
ベルタム,J.(Bertam,J.)(1999)、カロチノイド及び遺伝子調節(Carotenoids and gene regulation.)、栄養学概説(Nutr.Rev.)、57:182〜191。
ビヤーケン(Bjerkeng)ら、養殖(Aquaculture)、157、63〜82(1997)。
ブリトン,G.(Britton,G.)、FASEB J.、9、1551〜1558(1995)。
ブラウン(Brown)ら、アメリカ臨床栄養学雑誌(Am.J.Clin.Nutr.)、49、1258〜1265(1989)。
チュー(Chew)ら、動物科学雑誌(J.Anim.Sci.)、69、4892〜4897(1991)。
チュー(Chew)ら、動物科学雑誌(J.Anim.Sci.)、71、730〜739(1993)。
チェルベニー(Cerveny)ら、FASEB J.、13、A210(1999)。
チェルベニー(Cerveny)ら、FASEB J.、13、A210(1999)。
チュー,B.P.(Chew,B.P.)、栄養学雑誌(J.Nutr.)、125、1804S〜1808S(1995a)。
チュー,B.P.(Chew,B.P.)、ブタにおける繁殖に対するビタミン類の影響(The influence of vitamins on reproduction in pigs.)、動物栄養学における近年の進展(Recent Advances in Animal Nutrition.)(P.C.ガーンズワーシー(P.C.Garnsworthy)及びD.J.A.コール(D.J.A.Cole)編)、223〜239頁、ノッティンガム大学出版(Nottingham Univ.Press)、英国ノッティンガム(Nottingham)(1995b)。
チュー(Chew)ら、抗癌研究(Anticancer Res.)、19、1849〜1853(1999a)。
チュー(Chew)ら、抗癌研究(Anticancer Res.)、19、5223〜5227(1999b)。
チュー(Chew)ら、栄養学雑誌(J.Nutr.)、130、1788〜1791(2000a)。
チュー(Chew)ら、栄養学雑誌(J.Nutr.)、130、2322〜2325(2000b)。
コーンウェル(Cornwell)ら、脂質研究雑誌(J.Lipid Res.)、3、65〜70(1961)。
エステルバウアー(Esterbauer)ら、ニューヨーク学術科学年鑑(Ann.N.Y.Acad.Sci.)、570、254〜267(1989)。
グーリネット(Goulinet)及びチャップマン(Chapman)、動脈硬化、血栓症、血管生物学(Arterioscler.Thromb.Vasc.Biol.)、17、786〜796(1997)。
グッガー(Gugger)ら、栄養学雑誌(J.Nutr.)、122、115〜119(1992)。
ジュリアン(Julien)ら、循環研究(Circ.Res.)、49、248〜254(1981)。
ジョウノウチ(Jyonouchi)ら、栄養学的癌(Nutr Cancer)、21、47〜58(1994)。
ジョウノウチ(Jyounouchi)ら、栄養学雑誌(J.Nutr.)、125、2483〜2492(1995)。
ジョウノウチ(Jyonouchi)ら、栄養学的癌(Nutr.Cancer)、23(2)、171〜183(1995)。
ジョウノウチ(Jyonouchi)ら、栄養学的癌(Nutr.Cancer)、36、59〜65(2000)。
キム(Kim)ら、獣医免疫学・免疫病理学(Vet.Immunol.Immunopath.)、74、315〜327(2000a)。
キム(Kim)ら、獣医免疫学・免疫病理学(Vet.Immunol.Immunopath.)、74、331〜341(2000b)。
クリンスキー(Krinski)ら、生化学及び生物物理学記録(Arch.Biochem.Biophys.)、73、233〜246(1958)。
クラシゲ(Kurashige)ら、生理学・化学・物理学・医学NMR(Physiol.Chem.Phys.Med.NMR)、22、27〜38(1990)。
ロウラー(Lawlor)及びオブライエン(O'Brien)、栄養学研究(Nutr.Res.)、15、1695〜1704(1995)。
マーティン(Martin)ら、実用化学雑誌(J.Prakt.Chem.)、341、302〜308(1991)。
マシューズ−ロス,M.M.(Mathews-Roth,M.M.)、臨床化学(Clin.Chem.)、24、700〜701(1978)。
ミキ,W.(Miki,W.)、純粋応用化学(Pure Appl.Chem.)、63、141〜146(1991)。
ミヤモト(Miyamoto)ら、獣医医学雑誌(J.Vet.Med.Sci.)、57、347〜349(1995)。
ナギーブ,Y.M.A.(Naguib,Y.M.A.)、農産食品化学雑誌(J.Agric.Food Chem.)、48、1150〜1154(2000)。
ナカノ(Nakano)ら、生化学及び生物物理学記録(Biochemica et Biophysica Acta)、1426、119〜125(1999)。
ナカノ(Nakano)ら、農産食品化学雑誌(J.Agric.Food Chem.)、43、1570〜1573(1995)。
オルソン,J.A.(Olson,J.A.)、純粋応用化学(Pure Appl.Chem.)、66、1011〜1016(1994)。
オスタリー(Osterlie)ら、栄養学雑誌(J.Nutr.)、129、391〜398(1999)。
パロッツァ(Palozza)及びクリンスキー(Krinsky)、生化学及び生物物理学記録(Arch.Biochem.Biophys.)、297、184〜187(1992)。
パーク(Park)ら、栄養学雑誌(J.Nutr.)、128、1802〜1806(1998)。
パーク(Park)ら、栄養学的癌(Nutr.Cancer)、33、206〜212(1999)。
プア(Poor)ら、栄養学雑誌(J.Nutr.)、122、262〜268(1992)。
ロマンシク(Romanchik)ら、栄養学雑誌(J.Nutr.)、125、2610〜2617(1995)。
SAS(1991)SAS/STATユーザーズ・ガイド(User's Guide)、SASインスティテュート社(SAS Institute Inc.)、ノースカロライナ州カリー(Cary)。
シゲナガ(Shigenaga)ら、米国科学アカデミー紀要(Proc.Natl.Acad.Sci.)、91、10771〜10778(1994)。
タナカ(Tanaka)ら、発癌(Carcinogenesis)、15、15〜19(1994)。
テラオ.J.(Terao,J.)、脂質(Lipids)、24、659〜661(1989)。
テルプストラ(Terpstra)ら、分析生化学(Anal.Biochem.)、111、149〜257(1981)。
ワイスバーガー,J.H.(Weisburger,J.H.)、アメリカ臨床栄養学雑誌(Am.J.Clin.Nutr.)、53、226S〜237S(1991)。
Claims (12)
- アスタキサンチンを含む経口投与用組成物であって、イヌまたはネコに使用され、該組成物が炎症を軽減し、又は、免疫反応を増強し、該組成物が乾燥物を基準として20重量%〜50重量%のタンパク質を含む、該組成物。
- 前記組成物が、栄養的にバランスのとれたペットフード組成物である、請求項1に記載の組成物。
- 栄養的にバランスのとれたペットフード組成物が、ドッグフード組成物またはキャットフード組成物である、請求項2に記載の組成物。
- 前記組成物が栄養補助剤である、請求項2に記載の組成物。
- 炎症の軽減、または免疫の増強する方法であって、有効量のアスタキサンチンを含む組成物をコンパニオンアニマルに経口投与することを含む方法であって、該コンパニオンアニマルが、イヌまたはネコであり、該組成物が乾燥物を基準として20重量%〜50重量%のタンパク質を含む、該方法。
- 1日に0.02mg〜40mgのアスタキサンチンを前記コンパニオンアニマルに投与することを含む、請求項5に記載の方法。
- 前記免疫反応が細胞性免疫反応である、請求項6に記載の方法。
- 前記免疫反応が体液性免疫反応である、請求項6に記載の方法。
- 前記コンパニオンアニマルがイヌである、請求項6に記載の方法。
- 1日に0.1mg〜40mgのアスタキサンチンがイヌに投与される、請求項9に記載の方法。
- 前記コンパニオンアニマルがネコである、請求項6に記載の方法。
- 1日に0.02mg〜10mgのアスタキサンチンがネコに投与される、請求項11に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44507703P | 2003-02-05 | 2003-02-05 | |
PCT/US2004/003220 WO2004071211A1 (en) | 2003-02-05 | 2004-02-05 | Methods and compositions utilizing astaxanthin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006515178A JP2006515178A (ja) | 2006-05-25 |
JP4263192B2 true JP4263192B2 (ja) | 2009-05-13 |
Family
ID=32869312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005518375A Expired - Lifetime JP4263192B2 (ja) | 2003-02-05 | 2004-02-05 | アスタキサンチンを利用する方法及び組成物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20040151761A1 (ja) |
EP (1) | EP1589827B1 (ja) |
JP (1) | JP4263192B2 (ja) |
CN (1) | CN1744826A (ja) |
AR (1) | AR043113A1 (ja) |
AU (1) | AU2004211904A1 (ja) |
BR (1) | BRPI0407243A (ja) |
CA (1) | CA2514750C (ja) |
ES (1) | ES2636493T3 (ja) |
MX (1) | MXPA05008296A (ja) |
RU (1) | RU2005124966A (ja) |
WO (1) | WO2004071211A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011712A1 (en) * | 2003-07-25 | 2005-02-10 | Washington State University Research Foundation | Natural astaxanthin extract reduces dna oxidation |
JP4903569B2 (ja) * | 2003-09-12 | 2012-03-28 | アクセス ビジネス グループ インターナショナル エルエルシー | サイトカインモジュレータ及び関係する使用法 |
US7758903B2 (en) | 2003-09-12 | 2010-07-20 | Access Business Group International Llc | Cytokine modulators and related methods of use |
US7758902B2 (en) | 2003-09-12 | 2010-07-20 | Access Business Group International Llc | Cytokine modulators and related methods of use |
US8921422B2 (en) * | 2003-10-01 | 2014-12-30 | The Iams Company | Methods and kits for enhancing ability to learn in a puppy or kitten |
WO2005058064A1 (ja) * | 2003-12-19 | 2005-06-30 | Menicon Co., Ltd. | アスタキサンチン配合ペット用食物 |
CA2559974C (en) | 2004-03-17 | 2012-08-14 | Nestec S.A. | Compositions and methods for reducing or preventing obesity |
EP1755406B1 (en) * | 2004-04-16 | 2012-09-26 | Nestec S.A. | Compositions for reducing oxidative stress in an animal |
US20050266051A1 (en) * | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
AU2006253006B8 (en) * | 2005-05-31 | 2011-09-15 | Alimentary Health Ltd | Feline probiotic Lactobacilli |
BRPI0611492B1 (pt) * | 2005-05-31 | 2021-10-13 | Mars, Incorporated | Bifidobactéria probiótica felina |
JP2009514824A (ja) | 2005-11-02 | 2009-04-09 | ネステク ソシエテ アノニム | 雄の哺乳動物における体脂肪の蓄積を低減するためのイソフラボン組成物及びその使用方法 |
AU2006318357B2 (en) * | 2005-11-28 | 2009-09-24 | U.S. Nutraceuticals Llc Dba Valensa International | Algal and algal extract dietary supplement composition |
US7682619B2 (en) * | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
PL2663198T3 (pl) * | 2011-01-14 | 2019-05-31 | Iams Europe B V | Kompozycje związane z karotenoidami |
CN107846938A (zh) * | 2015-05-20 | 2018-03-27 | 印第安纳大豆联盟有限公司 | 通过鲑科鱼提高大豆蛋白利用率的方法 |
US20200205442A1 (en) * | 2018-12-28 | 2020-07-02 | Unicharm Corporation | Comprehensive nutrition pet food |
CN112515049A (zh) * | 2020-11-09 | 2021-03-19 | 南京未来宠物产业研究院有限公司 | 一种虾青素在制备功能性宠物食品中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356810A (en) * | 1987-04-15 | 1994-10-18 | Gist-Brocades N.V. | Astaxanthin-producing yeast cells, methods for their preparation and their use |
SE9401738D0 (sv) * | 1994-05-19 | 1994-05-19 | Ewos Ab | Bioactive feed |
SE503336C2 (sv) * | 1994-09-19 | 1996-05-28 | Asta Carotene Ab | Medel och sätt för att öka produktionen av/hos fjäderfän |
SE506191C2 (sv) * | 1996-03-27 | 1997-11-17 | Astacarotene Ab | Medel och sätt för att öka produktionen av/hos däggdjur |
US5937790A (en) * | 1996-12-18 | 1999-08-17 | Showa Denko Kabushiki Kaisha | Anti-stress agent for animals and a method of reducing stress in animals |
SE522246C2 (sv) * | 1997-02-27 | 2004-01-27 | Astacarotene Ab | Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion |
US6133323A (en) * | 1997-04-09 | 2000-10-17 | The Iams Company | Process for enhancing immune response in animals using β-carotene as a dietary supplement |
US6310090B1 (en) * | 1999-05-27 | 2001-10-30 | The Iams Company | Process and product for enhancing immune response in companion animals using a combination of antioxidants |
AU2002311758A1 (en) * | 2001-01-26 | 2002-10-15 | Cargill, Incorporated | Carotenoid biosynthesis |
WO2002098373A1 (en) * | 2001-06-01 | 2002-12-12 | Animal Health Ventures, Inc. | Methods and products for bad breath |
US6849288B2 (en) * | 2001-08-22 | 2005-02-01 | Solae L.L.C. | Soybean meal with a reduced fat and soluble sugar content, and methods of making and using the same |
AU2002365602A1 (en) * | 2001-12-04 | 2003-06-17 | Luis W. Levy | Supplements containing annatto extracts and carotenoids and methods for using the same |
-
2004
- 2004-01-23 US US10/764,215 patent/US20040151761A1/en not_active Abandoned
- 2004-02-05 CN CNA200480003244XA patent/CN1744826A/zh active Pending
- 2004-02-05 AU AU2004211904A patent/AU2004211904A1/en not_active Abandoned
- 2004-02-05 RU RU2005124966/13A patent/RU2005124966A/ru not_active Application Discontinuation
- 2004-02-05 EP EP04708561.8A patent/EP1589827B1/en not_active Expired - Lifetime
- 2004-02-05 MX MXPA05008296A patent/MXPA05008296A/es active IP Right Grant
- 2004-02-05 BR BR0407243-0A patent/BRPI0407243A/pt not_active Application Discontinuation
- 2004-02-05 WO PCT/US2004/003220 patent/WO2004071211A1/en active Application Filing
- 2004-02-05 ES ES04708561.8T patent/ES2636493T3/es not_active Expired - Lifetime
- 2004-02-05 JP JP2005518375A patent/JP4263192B2/ja not_active Expired - Lifetime
- 2004-02-05 CA CA002514750A patent/CA2514750C/en not_active Expired - Lifetime
- 2004-02-06 AR ARP040100376A patent/AR043113A1/es not_active Application Discontinuation
-
2016
- 2016-09-28 US US15/279,265 patent/US20170014356A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0407243A (pt) | 2006-01-31 |
US20170014356A1 (en) | 2017-01-19 |
ES2636493T3 (es) | 2017-10-05 |
AU2004211904A1 (en) | 2004-08-26 |
CA2514750C (en) | 2009-07-21 |
CN1744826A (zh) | 2006-03-08 |
EP1589827A1 (en) | 2005-11-02 |
EP1589827B1 (en) | 2017-05-03 |
MXPA05008296A (es) | 2005-09-20 |
US20040151761A1 (en) | 2004-08-05 |
RU2005124966A (ru) | 2006-02-10 |
CA2514750A1 (en) | 2004-08-26 |
AR043113A1 (es) | 2005-07-20 |
JP2006515178A (ja) | 2006-05-25 |
WO2004071211A1 (en) | 2004-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170014356A1 (en) | Methods of enhancing immunity in a companion animal | |
JP5680828B2 (ja) | 寿命を伸長するための栄養システム及び方法 | |
Ortuno et al. | High dietary intake of α-tocopherol acetate enhances the non-specific immune response of gilthead seabream (Sparus aurata L.) | |
AU2006251899B2 (en) | Methods for promoting health or wellness in adult animals | |
WO2018049243A1 (en) | Feed additive comprising allicin | |
MX2013004839A (es) | Metodo para mejorar la inmunidad de un animal de compania. | |
Hasan et al. | Benificial effects of probiotic on growth performance and hemato-biochemical parameters in broilers during heat stress | |
Akinleye et al. | The performance, haematology and carcass traits of broilers as affected by diets supplemented with or without biomin a natural growth promoter | |
Kairalla et al. | Effect of diet supplemented with graded levels of ginger (Zingiber officinale) powder on growth performance, hematological parameters, and serum lipids of broiler chickens. | |
Mohanad et al. | Effect of using natural apple vinegar, garlic powder (Alsin) and black bean seed on the immune system and some of characteristics of the blood broilers Ross 308 | |
JP2018535257A (ja) | 尾腺油を含有する組成物およびその使用方法 | |
Yazdanabadi et al. | Effect of arginine supplementation on growth performance, lipid profile, and inflammatory responses of broiler chicks challenged with coccidiosis | |
Ahmed et al. | Enhancement effect of Spirulina platensis extract on broiler chicks’ growth performance and immunity | |
AU2005222628B2 (en) | Pet food compositions containing an added boron source | |
Hassan et al. | Effect of dietary supplemental ginger on broiler performance, carcass characteristics and blood profile | |
AU2008202253B2 (en) | Methods and compositions utilizing astaxanthin | |
US20090226558A1 (en) | Organic/natural poultry feed additive | |
Edwards et al. | Influence of fiber source on apparent digestibility, rate of passage and fecal consistency in small felids fed a beef-based carnivore diet | |
Aguihe et al. | Haematobiochemical indices of broiler chickens fed probiotic supplemented shea kernel cake meal based diet | |
RU2786226C2 (ru) | Способы и композиции для повышения содержания кетоновых тел у животных | |
Köse et al. | Effects of feed rations containing egg powder in different proportions on growth performance, feed utilization, body composition and survival rate of rainbow trout (Oncorhynchus mykiss Walbaum, 1792) fry | |
Udeh et al. | Serum biochemistry profile and liver function indices of broiler chickens served dietary inclusion of probiotics (Saccharomyces cerevisiae) and enzyme | |
Tohidifar et al. | Effect of dietary Spirulina platensis Phycocyanin and Fucoidan supplementation on egg properties, blood parameters, and Bacteriological count of laying Japanese quails | |
Ahmed et al. | The impacts of dietary inclusion of soybean oil and linseed oil on growth performance, carcass yield, and health status of growing Japanese quail | |
Köse et al. | RESEARCH ARTICLE ARAŞTIRMA MAKALESİ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070724 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071024 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071102 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071126 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080124 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080813 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080911 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090203 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090210 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120220 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4263192 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130220 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140220 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |